Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | May 31, 2017 | June 02, 2017 |
| KINETA, INC./DEYMTX · Entity 77778 | Director · Executive Chair | April 01, 2021 | April 02, 2021 |
| MCKESSON CORPMCK · Entity 2904 | Director | August 17, 2020 | August 19, 2020 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Comm. Ops. | July 20, 2005 | July 22, 2005 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date May 31, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 15,000 |
Reported balance
After 2017-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-31 · Grant · Acquired 15,000 · Balance 15,000 F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017.
KINETA, INC./DE
Report date April 01, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2031-03-31 | Direct | 78,650 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 78,650 · Balance 78,650 F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021.
MCKESSON CORP
Report date August 17, 2020 · Filed August 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-17 transaction · row 1
1 source rowRow 1 · 2020-08-17 · Sale · Disposed 2,453 · Balance 0 |
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,714 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,714 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
VERTEX PHARMACEUTICALS INC / MA
Report date July 20, 2005 · Filed July 22, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2015-07-19 | Direct | 272,328 |
Reported balance
After 2005-07-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2005-07-20 · Grant · Acquired 18,000 · Balance 272,328 F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 15,638 · Balance 10,290 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,290 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 4,809,418 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 46,322 · Balance 0 F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 22, 2020 Filed Dec 28, 2020 19:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 72,496 | Not disclosed Strike: $8.16 | Not disclosed |
DisclosureSEC source: 0000899243-20-035259 · doc4.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,496 Underlying: Common Stock · 72,496 shares Expires 2028-12-08 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F5 · price: Received in the Merger in exchange for a stock option to acquire 343,841 shares of Yumanity, Inc. common stock for $1.72 per share. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on December 4, 2019. The remaining 75% vest in equal monthly installments over the subsequent three years. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 19:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 52,669 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-035259 · doc4.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Indirect · By the Coles 2016 Irrevocable Trust Disclosed balance after: 52,669 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F3 · price: The shares were received in exchange for 249,950 shares of Yumanity, Inc. common stock in connection with the Merger. Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 19:05 UTC | KINETA, INC./DE YMTX · Entity 77778 | GrantCommon Stock | 689,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-035259 · doc4.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,890 F1 · date: On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. F2 · price: The shares were received in exchange for 3,272,078.16 shares of Yumanity, Inc. common stock in connection with the Merger. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:57 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001237899-20-000048 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,039 Underlying: Common Stock · 11 shares Expires 2027-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 13, 2020 Filed Nov 13, 2020 22:57 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 11 | $345.47 | $3,800.17 |
DisclosureSEC source: 0001237899-20-000048 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2020 Filed Oct 30, 2020 20:13 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantStock Option (Right to Buy) · Derivative | 196,335 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0000899243-20-030025 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,335 Underlying: Common Stock · 196,335 shares Expires 2030-10-28 F1 · derivative.exercise_date: 50% of this option shall vest and become exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 19:35 UTC | MCKESSON CORP MCK · Entity 2904 | SaleCommon Stock | 2,453 | $156.77 | $384,559.26 |
DisclosureSEC source: 0001598100-20-000050 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 29, 2020 Filed Jul 31, 2020 22:59 UTC | MCKESSON CORP MCK · Entity 2904 | GrantCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001598100-20-000041 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,453 F1 · shares: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vested immediately and the reporting person elected to receive the underlying shares upon grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-20-000002 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:01 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000002 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| July 31, 2019 Filed Aug 1, 2019 19:15 UTC | MCKESSON CORP MCK · Entity 2904 | GrantCommon Stock | 1,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001598100-19-000014 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296 F1 · shares: Restricted Stock Units (RSUs) granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vested immediately and the reporting person elected to receive the underlying shares upon grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001237899-19-000002 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000002 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 22:41 UTC | MCKESSON CORP MCK · Entity 2904 | SaleCommon Stock | 1,350 | $128.69 | $173,731.50 |
DisclosureSEC source: 0001443873-18-000036 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Sale in accordance with a previously adopted plan dated 7/31/2018 pursuant to Rule 10b5-1(c). Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 22:05 UTC | MCKESSON CORP MCK · Entity 2904 | GrantCommon Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001443873-18-000027 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350 F1 · shares: Restricted Stock Units (RSUs) granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vested immediately and the reporting person elected to receive the underlying shares upon grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,909 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001237899-18-000006 · edgardoc.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,909 Underlying: Common Stock · 6,909 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 26, 2017 Filed Jul 27, 2017 21:41 UTC | MCKESSON CORP MCK · Entity 2904 | GrantRestricted Stock Units (RSUs) · Derivative | 1,083 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001444054-17-000019 · edgar.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,083 Underlying: Common Stock · 1,083 shares Expires not disclosed F1 · derivative.exercise_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred unitl the Director leaves the Board. F1 · derivative.expiration_date: RSUs granted pursuant to an automatic annual grant under the 2013 Stock Plan. This grant vests immediately, however, receipt of the underlying shares is deferred unitl the Director leaves the Board. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0000899243-17-015162 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 22:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,050 | $0.00 Strike: $345.47 | $0.00 |
DisclosureSEC source: 0001104659-17-005427 · a4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,050 Underlying: Common Stock · 13,050 shares Expires 2027-01-27 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 35,000 | $14.00 | $490,000.00 |
DisclosureSEC source: 0000899243-16-032310 · doc4.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Coles Family Trust Disclosed balance after: 70,000 Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 22:28 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantCommon Stock | 35,000 | $14.00 | $490,000.00 |
DisclosureSEC source: 0000899243-16-032310 · doc4.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 70,000 Read SEC document |
| October 18, 2016 Filed Oct 20, 2016 21:16 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-16-032071 · doc4.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2026-10-18 F1 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning October 31, 2016. Read SEC document |
| July 20, 2005 Filed Jul 22, 2005 19:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-05-000044 · edgar.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,328 Underlying: Common Stock · 18,000 shares Expires 2015-07-19 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 24,750 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000008 · edgar.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,328 Underlying: Common Stock · 24,750 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,700 | $0.01 | $57.00 |
DisclosureSEC source: 0000875320-05-000008 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,540 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 02/03/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000106 · edgar.xml · derivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,578 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| May 06, 2004 Filed May 10, 2004 20:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 65,000 | $0.01 | $650.00 |
DisclosureSEC source: 0000875320-04-000050 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,840 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 50% on May 6, 2009, subject to acceleration upon achievement of a performance-based milestone based on Company profitability, and 50% on May 6, 2007. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 14,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-04-000019 · edgar.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,578 Underlying: Common Stock · 14,400 shares Expires 2014-03-16 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 03/17/2004. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.01 | $19.20 |
DisclosureSEC source: 0000875320-04-000019 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 3/17/2008, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 14,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-03-000057 · edgar.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,178 Underlying: Common Stock · 14,400 shares Expires 2013-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:21 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-03-000057 · edgar.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · SVP, Comm. Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting in 4 equal annual installments from 12/11/2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.